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Abstract 
Introduction 
Adolescents, relative to adults, show impairments in learning to reduce or extinguish fear. 
Furthermore, they may struggle with the use of reappraisal techniques to regulate affect. Both 
learning and reappraisals are critical to cognitive-behavioural treatments (CBT) for anxiety 
disorders leading to the hypothesis that adolescents may respond more poorly to CBT than 
adults.  
Methods 
We use meta-regression to explore whether variability in the mean age of participants in trials 
of CBT for anxiety predicted variability between studies in symptom change effect sizes. 
PsycARTICLES, PsycINFO, MEDLINE and Embase databases were searched with the terms 
exposure and each of anxiety, phobia, or panic disorder diagnostic terms and cognitive 
behav* therapy with each of the diagnostic terms. Data were pooled from CBT trials for 
anxiety disorders (excluding anxiety-related disorders – obsessive compulsive disorder and 
posttraumatic stress disorder) where participants’ mean age was 11 years or older.  
149 studies were selected and data on change in symptoms from pre-treatment to post-
treatment (k = 195), pre-treatment to follow-up (k = 108) and post-treatment to follow-up (k = 
107) were extracted.  
Results 
Several possible confounding variables were also accounted for (e.g., proportion of females, 
number of sessions). Younger age was associated with smaller improvement in anxious 
symptoms from pre- to post-treatment. However, younger age was also associated with 
greater improvement in symptoms from post-treatment to follow-up. 
Conclusions 
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CBT is effective at reducing anxious symptoms, however, younger people may respond more 
slowly to treatment than older people.  
 
Keywords: Anxiety; Phobia; Adolescence; Exposure; Cognitive-Behavioural Treatment  
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Introduction 
Anxiety disorders pose considerable distress, disability and cost to individuals and 
economies worldwide (Baxter, Scott, Vos, & Whiteford, 2013; Baxter, Vos, Scott, Ferrari, & 
Whiteford, 2014). Many cases of anxiety begin in youth (Kessler, et al., 2005), posing 
significant long-term academic and social disadvantage (Van Ameringen, Mancini, & 
Farvolden, 2003). Young people with diagnoses of anxiety disorders such as specific phobia, 
social anxiety disorder, panic disorder and generalised anxiety disorder, are also at elevated 
risk of subsequent substance abuse and mood disorders in adulthood (Pine, Cohen, Gurley, 
Brook, & Ma, 1998). The gold-standard treatment for anxiety disorders – Cognitive 
Behavioural Therapy (CBT) – is highly efficacious in ameliorating anxiety symptoms 
(Bennett, et al., 2013; Berlim, Van den Eynde, & Jeff Daskalakis, 2013; Chorpita, et al., 
2011; Drysdale, et al., 2014; Hofmann & Smits, 2008; Kendall & Peterman, 2015). 
However, 40-50% of people will not respond to treatment (Walkup, et al., 2008) and, among 
those who do, up to 62% will experience a return of fear later (Craske & Mystkowski, 2006). 
For adolescents, they may be more likely than adults to show problems with the kind of 
learning and techniques that are thought to be critical to CBT for anxiety disorders, such as 
with extinction learning (Baker, Den, Graham, & Richardson, 2014) or in applying 
reappraisal techniques to regulate negative affect (McRae et al., 2012; Silver et al., 2012). 
Because of these age-typical differences, adolescents with anxiety may respond more poorly 
to CBT than anxious adults. Although there is a wealth of evidence from CBT studies 
involving either adolescents or adults with anxiety disorders, this research has yet to be 
combined meta-analytically to examine whether, across all existing studies, there are 
important age-related differences in CBT outcomes. The present study will provide the first 
such analysis with a view to informing our understanding of whether adolescents perform 
less well in CBT than adults. 
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CBT involves multiple treatment components such as psychoeducation, cognitive 
restructuring or reappraisal training and behavioural exposure. During the exposure 
component of CBT people are repeatedly exposed to the object of their fears. Extant 
research in this area suggests that exposure is perhaps the most important aspect of CBT 
(Wolitzky-Taylor, Horowitz, Powers, & Telch, 2008) and as such it is often delivered in a 
standalone format without the other components in adults and young people (Wolitzky-
Taylor et al., 2008; Chorpita, et al., 2011). Contemporary theories regarding exposure 
suggest that fear reduces or extinguishes as a person learns that a stimulus or situation that 
they fear (e.g., when their heart rate is perceived to be faster than usual in the case of panic 
disorder) is no longer predictive of the aversive outcome they expected would follow this 
stimulus/situation (e.g., that this pattern of heart activity is not predictive of an impending 
heart attack) (Bouton, 2004; Vervliet, Baeyens, Van den Bergh, & Hermans, 2013). In 
experimental models of extinction learning healthy adolescents (aged 10-17 years) have 
shown evidence of impairments such that their fear for discrete stimuli does not reduce 
across time (Haddad, Lissek, Pine, & Lau, 2011; Lau, et al., 2008) and when compared to 
adults (Britton, et al., 2013; Pattwell, et al., 2012). Furthermore, adolescents’ fear may be 
more likely than adults’ to return after it has been extinguished, again suggesting that the 
initial extinction learning was impaired (Britton, et al., 2013; Den, Graham, Newall, and 
Richardson, 2015). Similar age-related impairments in extinction learning have also been 
found in studies with juvenile rodents (Baker, Bisby, & Richardson, 2016; Baker & 
Richardson, 2015). It is also of note that amongst children and adolescents, poor extinction 
abilities measured prior to treatment have been associated with worse treatment responses 
(Waters & Pine, 2016).  
Cognitive reappraisal, another component of CBT, refers to the use of more effortful 
strategies to reinterpret an emotion-eliciting stimulus or situation to alter its meaning and 
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change its emotional impact. While this appears to be a promising way to regulate negative 
affect in adults, the adolescent capacity to deploy these strategies may be modulated by 
structural immaturity of neural circuits involved in top-down inhibition of affective 
responses. Experimental studies comparing cognitive reappraisal abilities in children, 
adolescents and adults have shown linear but also quadratic relations between age and 
regulation success. Put otherwise, the ability to effectively down-regulate emotions evoked 
by negative stimuli, using behavioural but also neural indices of affect, develops throughout 
adolescence and into adulthood (McRae et al., 2012; Silvers et al., 2012).    
Given the comparative difficulty with extinction learning and cognitive reappraisal 
ability that adolescents show relative to adults, and the importance of this learning in CBT 
for anxiety disorders, we might infer from this that anxious adolescents may show greater 
difficulty in responding to treatment compared with adults. It must be noted that although 
adolescents and adults differ in many of these comparisons when considered categorically, 
adolescence is a dynamic stage of life where there is tremendous biological, psychological 
and social change. In particular, during adolescence prefrontal brain regions known to be 
important in the management of fear and anxiety undergo significant maturation (Caballero, 
Granberg & Tseng, 2016). As such, we might expect there to be continuous change across 
adolescence into adulthood in responsiveness to CBT. Such age-related differences in 
treatment responses would contrast with the intuitive presumption that anxiety disorders 
would be more easily treated at earlier ages because these disorders had presumably 
emerged not long before treatment. This is relative to anxiety disorders that are treated in 
adulthood that might have emerged much earlier in life. Although some meta-analytical 
research has already compared CBT outcomes between children and adolescents, with no 
evidence of a difference between these age groups in CBT effectiveness (Bennett, et al., 
2013; Drysdale, et al., 2014; Kendall & Peterman, 2015), no meta-analyses of the effects of 
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age in the adolescent-to-adult age range have been conducted. It is important that such an 
analysis takes a continuous approach to age given the change that takes place across 
adolescence. Our findings might support the need for further adoption of extinction-
enhancing techniques (see Craske, Treanor, Conway, Zbozinek, & Vervliet, 2014) or more 
targeted strategies to encourage the use of cognitive reappraisal in treatments involving 
adolescents. 
Meta-regression techniques were used to examine whether the mean age of 
participants within a study group predicted differences between studies in the extent to 
which symptoms changed across and following treatment. We hypothesised that across 
analyses of symptom change from pre-treatment to post-treatment and pre-treatment to 
follow-up, the age of participants would show a positive association with study effect sizes. 
We expected that smaller effects, or less decrease in symptoms from pre-treatment, would 
be associated with younger age. Also, given the evidence that adolescents may be more 
likely to show a return of fear after extinction than adults, we also hypothesised that age 
would show a negative association with study effect sizes in our analysis of change in 
symptoms from post-treatment to follow-up. Put otherwise, we expected that younger age 
would be associated with greater increase in symptoms after treatment. 
To capture continuous age effects across adolescence and adulthood, we defined the 
lower age limit as 11 years in line with previous studies in this area (e.g., Bennett et al., 
2013). This age limit allowed us to exclude child samples where CBT is often delivered with 
parental input, concurrent treatments for other family members or without exposure. Also, 
this age represents the transition to independence that characterises adolescence as young 
people enter secondary education. Similarly, we defined the upper age limit of our adult 
sample as 60 years to remove any confounds of age-associated cognitive decline with 
responsiveness to CBT treatments (Evans, 2007). 
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As our hypotheses partly related to the extinction mechanisms underlying the 
exposure component of CBT, it was important that any trials without this component or 
where parental factors might moderate any treatment effects were excluded. Given our 
particular interest in the exposure component of CBT we examined if there were differential 
effects on symptom change for trials involving exposure-alone versus CBT that includes 
exposure as well as other components such as cognitive reappraisal training. We considered 
potential covariates regarding sample characteristics, notably, whether there were effects of 
gender on symptom change. We also accounted for the number of treatment sessions and if 
the trial involved individual- or group- delivered treatment. However, we had no specific 
hypotheses regarding the presence of or direction of any possible effects of these variables. 
Method 
Search strategy 
Relevant studies were identified through a systematic search of four databases: 
PsycARTICLES, PsycINFO, MEDLINE and Embase, selecting all relevant articles from the 
earliest date for each journal within these databases until 21 October 2015 when the first 
search was completed. Due to the lengthy time taken for data extraction and analysis, an 
additional search was completed on 9 October 2017 to account for any additional 
publications. In total six database searchers were conducted: three searches with the term 
exposure and each of three diagnostic terms - anxiety, phobia, or panic disorder – and, then 
cognitive behav* therapy in combination with each of the three diagnostic terms. After this 
initial search, duplicates were removed and the titles and abstracts of studies were read for 
conformity to study selection criteria. Additional articles were included where they had been 
cited within selected articles but where our initial search had missed them. 
Study selection 
AGE DIFFERENCES ANXIETY TREATMENT   8 
Included studies involved CBT or exposure therapy alone involving participants older 
than 11 years of age and younger than 60 years with a primary diagnosis of an anxiety 
disorder, who had not already been marked as treatment resistant and whose treatment was 
focused on a primary diagnosis and not some other comorbid disorder. Studies involving 
CBT were inspected to ensure that the treatment delivered in this study included an exposure 
component. Also, groups within studies that received any other technique for augmenting 
treatment were excluded (e.g., attention modification or pharmaceutical agents), but groups 
that received exposure or CBT in combination with a placebo were included. Treatments did 
not necessarily have to be delivered in-person by a clinician but exposures had to be 
clinician-supervised to ensure that they were adhered to fully, as our main study hypotheses 
involved the effects of age on learning during exposure. Studies involving imaginal or virtual 
reality exposure, as well as the more typical in vivo exposure, were included. Single case 
studies or studies using participants with sub-threshold symptom severity were excluded. 
Studies were excluded if they involved treatment of disorders in other family members (e.g., 
the treatment of parents’ anxiety). Studies where treatment also focused on response 
prevention or solely on imaginal exposure, and studies which involved anxiety-related 
disorders such as in Obsessive-Compulsive Disorder (OCD) and Post-traumatic Stress 
Disorder (PTSD), were excluded from the present analysis. See Figure 1 for a flow chart of 
the search and study identification process. 2710 studies were identified in the initial search 
and, after exclusion, 149 studies remained, within which there were 195 effect sizes for pre-
treatment to post-treatment (N = 8144), 108 effect sizes for pre-treatment to follow-up (N = 
3780) and 107 effect sizes for post-treatment to follow-up (N = 3728) comparisons. 
Data extraction 
The following data were extracted from each article by T.J.B. and S.P.Y.: 1) author(s) 
name; 2) year of publication; 3) sample size at pre-treatment, post-treatment and  follow-up; 
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4) mean age of the sample; 5) data regarding the primary diagnosis of the sample (e.g., 
specific phobia, social anxiety disorder, panic disorder, generalised anxiety disorder or 
‘mixed’ where the trial involved participants with a range of anxiety diagnoses); and, 6) 
mean score and standard deviation for the primary outcome measure at pre-treatment, post-
treatment and follow-up. Where several primary outcomes were included in a study, 
clinician-rated measures (e.g., scores from clinical interviews) were extracted if they were 
available, otherwise self-rated measures (e.g., questionnaires) were extracted. These 
measures took priority over other kinds of measure such as Behavioural Avoidance Tests 
(BATs) as these behavioural measures were far less common within the literature. Regarding 
follow-up data, where a study had several follow-up assessments, data from the assessment 
most distant in time from post-treatment were extracted. 
Data regarding potential covariates were also extracted: 1) percentage of female 
participants; 2) number of treatment sessions; 3) whether the trial was individual or group 
treatment (coded as 0 and 1 respectively); 4) whether the trial involved exposure alone or 
exposure as part of a larger CBT program (coded as 0 and 1 respectively). Our index of the 
number of treatment sessions did not code for differences in session duration as few studies 
were explicit about the length of each individual session.  
Data handling and analysis 
The metan and metareg packages of STATA 14.2 were used for analyses. Data were 
analysed using a random effects framework that assumes that the effect of treatment on 
anxious symptoms varies between studies. This enables greater generalisation from the 
studies analysed here to other studies within the field. Pooled standard mean differences (d) 
were computed using Cohen’s method. Between study heterogeneity was estimated using the 
DerSimonian and Laird method and tau-squared (𝜏2) served as the index of between study 
heterogeneity (Borenstein, Higgins, Hedges, & Rothstein, 2017). Thus, standard mean 
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differences and 95% confidence intervals (CI) were given for each effect size with 
adolescent and adult samples, for each time point of interest: change from pre-treatment to 
post-treatment, change from pre-treatment to follow-up and change from post-treatment to 
follow-up. The significance of these pooled ds was calculated using a Z test. To reduce the 
effect of outliers on our analyses, within each time point, effect sizes that were 3 or more 
standard deviations greater than or less than the mean effect size for that time point were 
excluded from analyses. Four effect sizes were excluded from pre- to post- treatment 
analysis (Beidel et al., 2014; Soravia et al., 2014; Spence et al., 2017; Spence et al., 2011). 
Three effect sizes were excluded from pre- to follow-up analysis (Marks et al., 1993; Spence 
et al., 2011; Spence et al., 2017). Two effect sizes were excluded from post- to follow-up 
analysis (Spence et al., 2011; Spence et al., 2017).  
We first present the overall size of the effect for change in symptoms for each of the 
time points across age groups, and an estimation of the amount of variance between studies 
in the size of the effect sizes. Where there was evidence of significant variance in the size of 
effects, for descriptive purposes we then present a categorical meta-analysis of each age 
group separately. This was followed up by random effects meta-regression to explore age as 
a continuous predictor of symptom change for each of the time points. Where there was 
evidence of a significant linear relationship between age and symptom change, additional 
potential confounds were entered into the meta-regression to explore whether the variance in 
treatment change that was explained by age was independent of these confounds (e.g., 
proportion of females, the number of treatment sessions, whether the trial was mere 
exposure or exposure within a larger CBT package and whether treatment was delivered at 
an individual or group level). The independent effects of each of the included variables with 
the meta-regressions was calculated using a Z test. 
AGE DIFFERENCES ANXIETY TREATMENT   11 
We then explored whether there was evidence of publication bias, first by visually 
inspecting funnel plots and then statistically using Egger’s test to assess whether effect sizes 
were related to sample sizes. Vevea and Woods’ (2005) sensitivity analysis was then 
performed, which adjusts pooled effect sizes based on the presence of moderate and severe 
one- and two-tailed selection biases. The absence of publication bias in this test is evidenced 
by similarity in these adjusted and unadjusted effect sizes.  
Results 
 Sample-wide, adolescent and adult group sample characteristics are displayed in 
Table 1. A full list of references of included studies and forest plots of effect sizes is 
available in the supplemental materials. 
Pre- to post- treatment  
Across both age groups, there was a large effect of treatment on change in anxiety 
symptoms (d = 1.302, CI[1.203, 1.401], Z = 25.79, p < .001). There was also a substantial 
amount of variance between studies in the size of the change in symptoms from pre- to post- 
treatment (𝜏2 = .392, χ2(194) = 1424.78, p < .001). Separating adolescents (>11 years of age 
and < 19 years of age) from adults (>/=19 years) categorically for descriptive/interpretative 
purposes, both adults (d = 1.321, CI[1.214, 1.427], Z = 24.22, p < .001) and adolescents (d = 
1.189, CI[.924, 1.453], Z = 8.81, p < .001) showed significant change in symptoms from pre- 
to post- treatment.  
 In a meta-regression including mean age for each effect size as a predictor variable, 
and the effect size for change from pre- to post- treatment as the dependent variable, age 
explained a trend-level amount of variance in symptom change effect sizes (B = .012, SE = 
.006, Z = 1.91, p = .056). The effect of age became significant when the additional potential 
confounds were included in the model (B = .013, SE = .007, Z = 1.97, p = .049). Of these 
other variables, only the proportion of females explained a significant amount of variance in 
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study effect sizes (B = .008, SE = .004, Z = 2.15, p = .032) (See Table 2 for full description 
of meta-regression findings). This model explained 3.7% of the variance in effect sizes for 
symptom change. Older age was associated with greater decrease in symptoms from pre- to 
post-treatment, however, the amount of between-study variance in symptom change that was 
explained by participants’ age was small. Studies that had a higher proportion of females 
also showed greater decrease in symptoms. 
Pre-treatment to follow-up 
 Overall there was a large effect of treatment on change in anxious symptoms from 
pre-treatment to follow-up (d = 1.457, CI[1.314, 1.599], Z = 20.06, p < .001) with substantial 
variance between studies in the size of this effect (𝜏2 = .449, χ2(107) = 772.86, p < .001). 
Separating the groups categorically, effect sizes for change in symptoms from pre-treatment 
to follow-up assessment were similar for adults (d = 1.435, CI[1.275, 1.595], Z = 17.56, p < 
.001) and adolescents (d = 1.562, CI[1.272, 1.853], Z = 10.54, p < .001).  
 In a meta-regression, age was not a significant predictor of change in symptoms from 
pre-treatment to follow-up (B = .001, SE = .007, Z = .17, p = .863). 
Post-treatment to follow-up 
 Across the age groups there was evidence of a significant reduction in symptoms 
from the end of treatment to follow-up assessment such that symptoms continued to decrease 
after treatment (d = .213, CI[.148, .279], Z = 6.37, p < .001). There was also a significant 
amount of variance between studies in the size of this decrease ( 𝜏2 = .045, χ2(106) = 190.14, 
p < .001). Both age groups showed positive pooled effect sizes such that symptoms 
continued to decrease from the end of treatment to follow-up with adolescents showing 
somewhat more change (d = .307, CI[.214, .401], Z = 6.44, p < .001) than adults (d = .190, 
CI[.112, .269], Z = 4.77, p < .001). 
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In a meta-regression age explained a significant amount of variance in between-study 
differences in effect sizes for symptom change from post-treatment to follow-up assessment 
(B = -.007, SE = .003, Z = -2.19, p = .028). When the potential confounds were entered into 
the model, age continued to explain a significant amount of variance in between-study 
differences in symptom change (B = -.007, SE = .003, Z = -2.28, p = .023). The only 
confound which explained a significant amount of variance in effect sizes was if treatment 
was delivered as exposure alone or a full package of CBT (B = .239, SE = .118, Z = 2.03, p = 
.042). The direction of this effect was such that studies involving a full package of CBT 
were associated with greater decrease in symptoms from post-treatment to follow-up, 
compared with if exposure was delivered on its own. None of the other potential confounds 
explained a significant amount of variance in symptom change (p > .05) (See Table 2). This 
model explained 20.1% of the variance in symptom change. Studies with older participants 
showed less change in symptom severity from post-treatment to follow-up assessment than 
studies with anxious people who were younger.  
Publication bias 
 Funnel plots of effect sizes for each of the analysis time points against standard 
errors for these effects suggested that there was evidence of a publication bias in the data for 
pre-treatment to post-treatment symptom change (see Figure 2 for funnel plots). This was 
confirmed by Egger’s test, t(194) = 3.28, p = .001. However, Vevea and Woods (2005) 
adjusted effect sizes accounting for severe two-tailed bias were similar to the unadjusted 
effect sizes across age-groups, suggesting that if we were to account for this publication bias 
in our analysis this would not have had a marked influence on our analyses (adjusted d =  
1.276). Egger’s test for the other time points suggested that there was no evidence of a bias 
in the pre-treatment to follow-up, t(107) = .52, p = .605, or post-treatment to follow-up data, 
t(106) = -.55, p = .585. Again, Vevea and Woods (2005) adjusted effect sizes accounting for 
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severe two-tailed bias were similar to the unadjusted effect sizes for overall symptom change 
across age-groups (pre-treatment to follow-up adjusted d = 1.390; post-treatment to follow-
up adjusted d = .131) 
Discussion 
Adolescents relative to adults have been found to show difficulties in the extinction 
of fear (Baker, et al., 2014) and in reappraisal of negative affect (McRae et al., 2012; Silvers 
et al., 2012). These aspects of behavioural and cognitive emotion regulation are critical 
components of CBT for anxiety disorders (Craske, et al., 2008). This meta-analysis provided 
the first, and most comprehensive, examination of whether the age of adolescent and adult 
participants in trials of CBT would explain differences in treatment effect sizes. Combining 
the findings from each of the analyses performed here, there was evidence that older age was 
associated with greater reduction in symptoms from pre-treatment to post-treatment, but not 
symptom change from pre-treatment to follow-up. Also, younger age was associated with 
greater reduction in symptoms from post-treatment to follow-up. It must be noted, however, 
that age explained only a small amount of the heterogeneity in effect sizes between studies 
in our pre- to post- treatment analysis. There was also evidence that while older people may 
have responded better to CBT by post-treatment, younger people’s symptoms continued to 
decrease after post-treatment such that there was no difference between age-groups in their 
symptoms by follow-up assessment. Despite the observed effect of age on symptom change, 
it is worth underscoring that both age groups, when separated categorically, showed 
substantial treatment effects. Clearly, CBT for anxiety disorders is highly effective in 
reducing symptoms.  
 Our study sampled the totality of existing evidence regarding CBT for anxiety 
disorders across adolescence and adulthood. Our results from pre-treatment to post-treatment 
but not from pre-treatment to follow-up could be attributed to the suggestion that adolescents 
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show slowed extinction relative to adults (Britton, et al., 2013). Adolescents may take longer 
to consolidate the learning that takes place in treatment. It could also be that adolescents 
need more practice before they are competent with using reappraisal strategies and may also 
receive additional support from their families in these coping styles following treatment to 
the benefit of their anxious symptoms. Research must now examine what factors explain this 
continued improvement in symptoms, outside of treatment amongst adolescents. Another 
interpretation could be that older participants merely had increased symptom severity at pre-
treatment compared with younger participants so they showed a sharper decline in symptoms 
by post-treatment. However, if this was the case we would either expect the same age-related 
trend in our post-treatment to follow-up analysis as older participants’ symptoms continued 
to reduce or we would expect no age effect if younger participants had such low symptom 
severity that their symptoms could not further decrease during or after treatment.  
Our findings contrast with the intuitive expectation that responsiveness to treatment 
would be best in adolescence because the time of disorder onset is presumably nearer to 
treatment than would be the case for adults. As disorder onset time is rarely, if ever, 
quantified, we were unable to provide a definitive examination of this question. It would be 
interesting to examine whether disorder onset time moderates any of the observed effects. It 
must be noted that although our hypotheses were derived from evidence suggesting that 
adolescents show an impairment in extinction learning and reappraisal ability relative to 
adults, we did not examine whether age-related differences in these behavioural and 
cognitive aspects of emotion regulation directly explained age-related differences in 
treatment responses. It is possible that adolescents and adults may differ in their initial 
responsiveness to CBT for other reasons such as age-related differences in social or 
therapeutic processes such as a failure to align treatment to the desire for autonomy in 
adolescents or, more broadly, to use developmentally appropriate language and treatment 
AGE DIFFERENCES ANXIETY TREATMENT   16 
materials that are sensitive to adolescent norms (Kendall & Peterman, 2015). Future research 
must quantify these other possible factors as well as extinction and reappraisal problems in 
examining age-related differences in treatment responses.  
It is important to note that age only explained a small amount of variance in 
treatment effect sizes from pre- to post- treatment. Neither adolescents nor adults are 
homogenous groups of people and there are multiple factors that might explain differences 
in treatment responses between individuals besides their age. Such intra-age-group 
variability is perhaps particularly prominent in adolescence where there is substantial 
biological, psychological and social change. In order to examine the processes that influence 
treatment responsiveness amongst adolescents, research must now examine whether 
variability in these characteristics, perhaps in the underlying neurobiology of fear and 
anxiety (Milad & Quirk, 2012; Vervliet et al., 2013), explains additional variance in 
treatment responsiveness. It is also of note that although we found evidence of publication 
bias within the analysis of symptom change from pre-treatment to post-treatment, our 
sensitivity analysis showed that the inclusion of unpublished data would be unlikely to 
change the overall findings for symptom change across adults and adolescents. 
Two other findings emerged from our analysis of potential covariates. First, that 
studies with a higher proportion of females showed greater decreases in symptoms from pre-
treatment to post-treatment and second, that studies involving a full package of CBT were 
associated with greater decrease in symptoms from post-treatment to follow-up relative to 
studies involving exposure alone. The gender effect might be explained by differences in the 
therapeutic relationship between males and females (Bhati, 2014; Wintersteen, Mensinger & 
Diamond, 2005), with females responding more strongly to the therapeutic environment than 
males, and so responding more rapidly to treatment. Nevertheless, given that there were no 
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gender effects by follow-up it seems that both genders are equally likely to respond well to 
treatment over the longer term.  
The finding that CBT was associated with greater decrease in severity from post-
treatment to follow-up versus exposure alone is not entirely clear given that this variable was 
not associated with symptom change from pre-treatment to post-treatment or pre-treatment 
to follow-up. These findings suggest that neither treatment form is better than the other at 
modifying symptom trajectories from pre-treatment. It could be that some other component 
of CBT besides exposure might exert change on symptoms in a delayed manner following 
treatment cessation. However, future research must clarify this point in comparisons of CBT 
and exposure alone with mediational analyses during follow-up periods. 
Although the effect of age observed here were small, we might nonetheless offer 
some recommendations to clinicians to enhance treatment responsiveness. Given the 
suggestion that adolescents may respond less well to CBT initially, clinicians might adopt 
techniques already more common in the treatment of adult anxiety for enhancing treatment 
learning (Craske et al., 2014). For example, clinicians could ensure that greater attention is 
given to establishing what it is an anxious adolescent expects when they are in the presence 
of a feared stimulus and then focus on violating this expectancy. They might also vary 
stimuli and situations as much as possible within treatment and present as many of them as 
possible, concurrently where possible, whilst removing safety behaviours, encouraging 
clients to label their emotional experiences and ensuring that attention stays maintained on 
feared stimuli during exposure. Although these practices may already be utilised by some 
clinicians, it remains unclear whether the most evidence-based approaches are being utilised 
fully by clinicians (Chorpita et al., 2011) and whether this includes exposure with an 
emphasis on enhancing extinction learning (Wolitzky-Taylor, Zimmermann, Arch, De 
Guzman & Lagomasino, 2015). In terms of reappraisal techniques, there are also 
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experimental interventions designed to encourage the re-interpretation of negative stimuli to 
a more benign focus. As an example, cognitive bias modification techniques, while currently 
yielding weak effects in single-session studies (Krebs et al., 2018), could be optimised 
across multiple sessions with more engaging stimuli to reduce anxiety (Lisk et al., 2018). 
Functional MRI based neurofeedback to enhance cognitive reappraisals also shows promise 
particularly if one of the reasons for difficulties is the immaturity of prefrontal inhibition of 
affective responses in subcortical regions (Cohen Kadosh et al., 2016). As such, if 
adolescents are more likely to respond more slowly to treatment than adults then greater 
emphasis should be placed on establishing whether these experimental techniques could 
enhance extinction learning and cognitive reappraisals. 
Limitations 
It is notable how few groups of data there were for adolescents compared with adults. 
For this reason, we were relatively liberal in our inclusion criteria of selecting studies where 
the mean age was 11 years. However, a downside of this was that younger children were 
also included in the meta-analysis given that a sample where the mean age is 11 is likely to 
include pre-adolescent children. This seems unavoidable given that, as reported elsewhere 
(Kendall & Peterman, 2015), many trials in this area have liberal criteria for what constitutes 
adolescence and as such often involve younger children as well. Many of these studies also 
often involve mixed samples of several different diagnostic groups. We were unable to 
identify any studies within our inclusion/exclusion criteria involving adolescent participants 
where treatment was specifically for Panic Disorder or Generalised Anxiety Disorder, 
although these disorders were included in some of the mixed-diagnosis studies that were 
included (Nauta, Scholing, Emmelkamp, & Minderaa, 2003; Shechner, et al., 2014). The 
level of heterogeneity that is expected amongst these age groups and between diagnoses 
made it difficult to fully and robustly examine the effects of CBT and exposure on anxiety 
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symptoms within adolescence or to explore disorder specific effects. It is also possible that 
adolescents were more likely to be medication naïve than adults given that adolescents were 
unlikely to have been diagnosed as anxious for as long as adults. However, medication use 
was not consistently reported across the studies that were sampled. This prevented us from 
exploring whether differences in the use of medication between adolescent and adult 
samples had any influence on the observed effects.  
In our analysis of follow-up data, we extracted data from the latest follow-up time 
point within each study. This time point varied across studies, and although it would be 
possible to analyse whether the length of time between post-treatment assessments and the 
last follow-up assessment further predicted effect sizes, and perhaps also interacted with age, 
these data were not extracted in the current study because there were no a priori hypotheses 
regarding this variable prior to our analysis. Future research, perhaps building on the data set 
presented here, could extract these data and examine these effects.  
Regarding the number of treatment sessions recorded in our analysis, studies either 
reported the total number of treatment sessions within a given study or the average number 
of treatment sessions that the participants in their study completed. This inconsistency 
between studies means that we could not definitively control for possible age-related 
differences in the number of treatment sessions completed and the potential effect of this on 
treatment responses. Also, there was inconsistency between studies regarding the length of 
time of a given session – some studies included fewer sessions but delivered treatment in a 
massed format across several hours.  
Conclusion 
We provide the first meta-analysis of age-related differences in treatment responses 
for anxiety disorders in adolescents and adults. Our highly comprehensive meta-analysis and 
meta-regression offers the strongest support yet for the suggestion that CBT and exposure 
AGE DIFFERENCES ANXIETY TREATMENT   20 
therapy are associated with large changes in anxiety severity but that younger people may 
respond more slowly to treatment than older people. Despite this finding, there is a relative 
lack of treatment trials in adolescence and even fewer studies examining ways in which 
treatment might be improved for this age group. By taking the broadest possible view of 
existing evidence in this area it has also become clear that there is a pressing need for greater 
quantity of research regarding the treatment of adolescent anxiety. In particular, there is a 
need for further examinations of the factors which moderate treatment within this group, 
perhaps in terms of individual differences in fear learning and extinction processes, cognitive 
reappraisal techniques or other therapeutic or social processes. 
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Table 1. Study characteristics 
  Pre-treatment to post-treatment  Pre-treatment to follow-up  Post-treatment to follow-up 
  Total Adol. Adults  Total Adol. Adults  Total Adol. Adults 
N 8144 1125 7019  3780 871 2909  3728 871 2857 
k 195 26 169  108 19 89  107 19 88 


















Females  64.0% 55.7% 65.3%  66.8% 59.3% 68.4%  66.8% 59.3% 68.4% 
Prop. 
diagnosis 
           
 Mixed 13.3% 53.8% 7.1%  12.0% 42.1% 5.6%  12.1% 42.1% 5.7% 
 SAD 34.9% 19.2% 37.3%  34.3% 26.3% 36.0%  32.7% 26.3% 34.1% 
 Specific 20.0% 26.9% 18.9%  26.9% 31.6% 25.8%  27.1% 31.6% 26.1% 
 Panic 26.2% 0.0% 30.2%  20.4% 0.0% 24.7%  21.5% 0.0% 26.1% 
 GAD 5.6% 0.0% 6.5%  6.5% 0.0% 7.9%  6.5% 0.0% 8.0% 
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Prop. CBT  68.7% 76.9% 67.5%  64.8% 68.4% 64.0%  63.6% 68.4% 62.5% 
Prop. Group 36.9% 34.6% 37.3%  33.3% 42.1% 31.5%  32.7% 42.1% 30.7% 
 
Note. Total sample characteristics. Data are given for effect sizes with a mean age greater than 11 years and less than 19 years (Adol.: 
adolescents) and for effect sizes with a mean age greater than 19 (adults). Where means are given, standard deviations are presented in 
parentheses. Prop. Diagnoses refers to the proportion of effect sizes for each diagnostic category within a given age category. Sessions refers to 
the average number of treatment sessions. Prop. CBT refers to the proportion of effect sizes involving cognitive behavioural therapy, where the 
remaining effect sizes would be exposure alone. Prop. Group refers to the proportion of effect sizes involving group therapy, where the 
remaining percentage would be individual therapy Mixed: Studies with participants from several diagnostic groups; SAD: Social Anxiety 
Disorder; Specific: Specific Phobia; Panic: Panic Disorder; GAD: Generalized Anxiety Disorder.
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Table 2. Meta-regression 
  Pre-tx to post-tx  Post-tx to follow-up 
 Beta SE Z  Beta SE Z 
Step 1        
 Age .012 .006 1.91+  -.007 .003 -2.19* 
         
Step 2        
 Age .013 .007 1.97*  -.007 .003 -2.28* 
 Gender .008 .004 2.15*  .002 .002 1.29 
 Sessions -.008 .016 -.51  -.008 .010 -.083 
 Exp. or CBT -.090 .185 -.49  .239 .118 2.03* 
 Individual or Group .177 .138 1.28  -.125 .072 -1.73 
 
Note. Meta-regression predicting change in symptoms from pre-treatment (pre-tx) to post-
treatment (post-tx) and from post-treatment to follow-up assessments, where mean age is 
entered in the first step and potential confounds are added in the second step. Results are not 
presented for our analysis of pre-treatment to follow-up symptom change as age was not a 
significant predictor in the first step of that meta-regression. Gender refers to the proportion 
of females. Sessions refers to the average number of treatment sessions. Exp. or CBT refers 
to whether or not treatment was exposure therapy alone or cognitive behavioural therapy. 
Individual or group refers to whether or not the treatment was delivered in an individual or 
group format. +: p = .06; *:p < .05.  
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Figure 1. Study search and inclusion/exclusion 
 
Note. Flow chart of article inclusion and exclusion. OCD: Obsessive Compulsive Disorder; 
PTSD: Post-traumatic Stress Disorder; pre-tx: pre-treatment; post-tx: post-treatment; FU: 
Follow-up.
2710 studies identified from databases
574 duplicates removed
2136 studies screened (title)
1508 excluded (not relevant) 
628 studies screened (abstract)
261 excluded (not relevant)
367 studies screened (full text)
136 excluded 
10 unable to source 
11 not English 
111 data not given 
4 not primary diagnosis
259 studies remaining
28 additional articles identified 
from other sources (e.g., reference 
sections, authors personal library)
110 excluded  
34 (mean age <11 years) 
69 OCD 
7 PTSD
149 studies selected 
203 effect sizes 
195 pre-tx to post-tx 
108 pre-tx to FU 
107 post-tx to FU 
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Figure 2. Funnel plots 
 
Note. Funnels plots of effect sizes (SMD: Standard Mean Difference (Cohen’s d)) for symptom change for the three time points (from left to 
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